English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Neovacs and Biosense Sign Option Agreement for Chinese Development and Commercialization for Lupus and Dermatomyositis Treatment

Feb. 21, 2017

Neovacs and BioSense Global LLC have signed a commercial license option agreement for the IFNα Kinoid vaccine to treat lupus and dermatomyositis in China. The agreement is worth up to €65 million in upfront and milestone payments, not including double-digit sales royalties.